Neoadjuvant therapy for resectable pancreatic cancer suggested by Alan Burguete-Torres

Alan Burguete-Torres, Gastrointestinal Cancer Specialist at Centro Médico Zambrano Hellion, shared a post on X:

“New study on neoadjuvant therapy for resectable pancreatic cancer shows no improvement in overall survival rates. This highlights the need for further research to optimize treatment strategies.”

Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer: reconstructed patient-level meta-analysis of randomized clinical trials

Authors: Daniel Aliseda, Pablo Martí-Cruchaga, Gabriel Zozaya, Nuria Blanco, Mariano Ponz, Ana Chopitea, Javier Rodríguez, Eduardo Castañón, Fernando Pardo and Fernando Rotellar.

Source: Alan Burguete-Torres/X